First Week of March 22nd Options Trading For Celldex Therapeutics (CLDX)

Investors in Celldex Therapeutics, Inc. ( CLDX) saw new options begin trading this week, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLDX options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

The put contract at the $29.00 strike price has a current bid of $3.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $29.00, but will also collect the premium, putting the cost basis of the shares at $26.00 (before broker commissions). To an investor already interested in purchasing shares of CLDX, that could represent an attractive alternative to paying $29.16/share today.

Because the $29.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 10.34% return on the cash commitment, or 64.04% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of Stocks with Recent Secondaries »

Below is a chart showing the trailing twelve month trading history for Celldex Therapeutics, Inc., and highlighting in green where the $29.00 strike is located relative to that history:

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today